Previous research has demonstrated significantly improved glycemic outcomes in people with type 1 diabetes (PWT1D) and type 2 diabetes (PWT2D) who initiated use of Control-IQ technology by updating their existing pump software. This study examined glycemic outcomes by prior therapy (excluding software updaters) for PWT1D and PWT2D after they onboarded to Control-IQ technology. We performed retrospective analyses involving PWT1D and PWT2D from the US who purchased a new Tandem pump with Control-IQ technology and uploaded their pump data to t:connect® web application from Tandem Diabetes Care as of December 7, 2020. In all, 29,732 participants (94% T1D, 6% T2D) were included in the analysis. Median age of the sample was 40 years and majority had been using an insulin pump as prior therapy (66%) while 34% were transitioning from MDIs. After receiving their Tandem pump, prior pump users started using Control-IQ technology earlier (median days: T1D=16, T2D=16) than prior MDI users (T1D=21 days, T2D=23 days), mainly reflecting additional training provided to prior MDIs to onboard successfully to the new system. After 180 days of starting Control-IQ technology, for prior pump users with T1D, TIR was 74% (median, IQR 65-81%) and time below <70mg/dl (TBR) was 1.2% (IQR 0.6-2.1%). For prior pump users with T2D, TIR was 76% (IQR 69-82%) and TBR was 0.5% (IQR 0.2-1.0%). For participants transitioning from MDI, Control-IQ technology resulted in TIR of 74% (IQR 64-83%) and 0.9% TBR (IQR 0.4-1.7%) for PWT1D and 74% TIR (IQR 63-84%) and 0.3% TBR (IQR 0.1-0.6%) for PWT2D. Irrespective of prior therapy, PWT1D changed their pump settings (e.g., basal rates, carbohydrate ratio) more frequently (median: 3) vs. PWT2D (median: 2). Using Control-IQ technology, both PWT1D and PWT2D (irrespective of prior therapy) achieved very similar TIR outcomes. However, T2D users showed lower rates of hypoglycemia (TBR) vs. their T1D counterparts.

Disclosure

J. W. Morberg: Employee; Self; Tandem Diabetes Care. H. Singh: Employee; Self; Tandem Diabetes Care. M. Mcelwee-malloy: Employee; Self; Tandem Diabetes Care. S. Habif: Employee; Self; Tandem Diabetes Care. A. Constantin: Employee; Self; Tandem Diabetes Care.

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.